Sagimet Biosciences Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 trading plans
During the quarter ended March 31, 2025, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act)adopted orterminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" (as those terms are defined in Item 408 of Regulation S-K).
Board composition
Effective May 6, 2025, George Kemble, Ph.D. will transition from his executive officer position as Executive Chairman, and will move into the role of non-executive Chair of the Board. Also, on May 6, 2025, our Board appointed Beth Seidenberg, M.D. to serve as Lead Independent Director of the Board, effective May 6, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.